Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

No studies found 4 · 50%GRADE not reported 0 · 0%Very low 0 · 0%Low 4 · 50%Moderate 0 · 0%High 0 · 0%

Outcomes · patients with the initial treatment of venous thromboembolism in patients with cancer

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

All‐cause mortality · patients with the initial treatment of venous thromboembolism in patients with cancer

Dalteparin showed no clear difference in mortality compared with tinzaparin (low certainty).

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
RR 0.86 [0.43, 1.73]
1 study · 113 participants
Low

Recurrent VTE · patients with the initial treatment of venous thromboembolism in patients with cancer

Dalteparin showed no clear difference in recurrent VTE compared with tinzaparin (low certainty).

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
RR 0.44 [0.09, 2.16]
1 study · 113 participants
Low

Major bleeding · patients with the initial treatment of venous thromboembolism in patients with cancer

Dalteparin showed no clear difference in major bleeding compared with tinzaparin (low certainty).

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
RR 2.19 [0.2, 23.42]
1 study · 113 participants
Low

Minor bleeding · patients with the initial treatment of venous thromboembolism in patients with cancer

Dalteparin showed no clear difference in minor bleeding compared with tinzaparin (low certainty).

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
RR 0.82 [0.3, 2.21]
1 study · 113 participants
Low

Quality of life ‐ not reported · patients with the initial treatment of venous thromboembolism in patients with cancer

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Postphlebitic syndrome ‐ not reported · patients with the initial treatment of venous thromboembolism in patients with cancer

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Thrombocytopenia · patients with the initial treatment of venous thromboembolism in patients with cancer

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found